GLPwatch
Dulaglutide-induced cerebral venous thrombosis in a patient with type 2 diabetes mellitus.
BMJ Case Rep · 2018
Last updated 2026-05-28A patient with type 2 diabetes taking dulaglutide for 3 weeks developed severe nausea and vomiting, leading to dehydration. This was linked to a rare case of cerebral venous thrombosis—a blood clot in the brain’s venous system—along with a stroke-like area in the brain. Doctors ruled out other causes before attributing the clot to the drug’s side effects.
AI summary of the abstract below.
| Journal | BMJ Case Rep, 2018 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.26 |
| NIH percentile | 16 |
| Molecules | dulaglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
Though patients with diabetes mellitus are at a high risk of atherothrombotic events, every such event should not be attributed to the disease itself. We present a case of a patient with diabetes with headache and blurring of vision for 3 days. Brain imaging revealed right transverse sinus thrombosis and acute infarct of the right posterior parieto-occipital region, predominantly in the posterior cortical watershed zone. The patient was on subcutaneous dulaglutide for 3 weeks and was having nausea and vomiting. Various causes of cerebral venous thrombosis were ruled out with appropriate laboratory investigations. Finally, cerebral venous thrombosis was attributed to dulaglutide-induced nausea and vomiting which led to severe dehydration.
Verbatim abstract via PubMed 30413453 ↗
Related research
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).